Alfentanil is a short acting analogue of fentanyl which is one-third as potent and has a higher therapeutic ratio than the parent compound as a result of its rapid elimination from plasma . Alfentanil provides haemodynamic stability during anaesthesia in patients with cardiac disease when used either as an induction agent or during total i.v. anaesthesia, or both (Sebel, Bovill and Van Der Haven, 1982) . Even after large doses of alfentanil, the time to awakening is short (DeLange, Stanley and Boscoe, 1981) , and this short duration of action has led to its use as an infusion during prolonged anaesthesia (Bower and Hull, 1982) .
The shorter duration of action of alfentanil makes it an attractive alternative to fentanyl, as a supplement to anaesthetic gases, in patients undergoing neurological procedures. Moreover, its more rapid termination of action compared with fentanyl makes retention of carbon dioxide after operation less likely (Stanski and Hug, 1982) , would minimize postoperative narcotic-induced somnolence, and would allow more prompt evaluation of neurological function following surgery.
This study was undertaken to determine the effects of high doses of alfentanil (0.32 mg kg" 1 i.v.) on cerebral blood flow and metabolism (CMRo 2 ) in the dog. In addition, the reactivity of the cerebral vasculature to hypercapnia and hypoxia, and to changes in mean arterial pressure, was determined. techniques were used. Eleven animals (group 1, n = 6; group 2, n = 5) were anaesthetized initially with pentobarbitone 30 mg kg" 1 i.v. bolus and supplemented with i.v. increments of 30 mg in response to pedal and ocular reflexes. Six animals (group 3, n = 6) were anaesthetized with alfentanil 0.32 mg kg" 1 i.v. plus pentobarbitone 1-2 mg kg" 1 and an infusion of alfentanil 0.32 mg kg" 1 h" 1 was administered continuously throughout the investigation. Additional increments of alfentanil 1 mg were given if movement or cardiovascular response to stimulation occurred during the surgical preparation. Pancuronium 3-4 mg i.v. was administered in all groups to minimize muscle contractions related to the electrocautery. Heparin 500 u kg" 1 i.v. was used in all groups as the anticoagulant.
SUMMARY
After the induction of anaesthesia, the trachea was intubated and the lungs ventilated utilizing a positive pressure respirator (Harvard Respiration Pump 607). Tidal volume and respiratory rate were adjusted to give an alveolar (end-expiratory) carbon dioxide concentration of 4 % as monitored by a carbon dioxide analyser (Beckman LB2). The analyser was calibrated regularly with mixtures of carbon dioxide in air analysed to a precision of 0.1%. One femoral artery was cannulated to permit the continuous monitoring of arterial pressure. The contralateral femoral artery was cannulated and utilized for the removal of blood during those parts of the study which dealt with alterations in arterial pressure. One femoral vein was cannulated and was utilized to return the cerebral venous outflow, while the other femoral vein was cannulated and used for infusion of fluids and drugs. Rectal temperature was maintained at 38 ± 1 °C using heating lamps. All pressures were measured with Statham P-23 transducers, and all data were recorded in a Gould-Brush recorder.
Measurement of cerebral blood flow
The technique used to measure cerebral venous outflow has been described previously (Rapela and Green, 1964) . The confluence of the cerebral sinuses was cannulated, and the lateral sinuses and occipital emissary veins were occluded with bone wax to eliminate communication between intracranial and extracranial venous circulations. From the confluence of the sinuses, blood was passed through a previously calibrated electromagnetic flow probe, before being returned to the dog via the femoral vein. With this technique approximately 50-70 % of the mass of the brain is drained at the confluence of the sagittal and straight sinuses (Rapela and Green, 1964) . Cerebral venous outflow pressure was measured upstream from the flow probe. The venous outflow pressure was maintained near 0 mm Hg by manipulation of the reservoir level. This pressure measures the resistance to the flow of blood induced by the flow transducer, because the outflow cannula was set at the level of the right atrium and all pressures were referred to this common zero reference plane. Brain perfusion pressure was estimated as systemic arterial pressure minus cerebral venous outflow pressure. Intracranial vascular resistance was calculated by dividing brain perfusion pressure by cerebral venous outflow.
The verification of the measurement of CBF utilizing this venous outflow technique has been described in detail elsewhere (Traystman and Rapela, 1975) ; the viability and reactivity of the cerebral vasculature to hypercapnia (Traystman and Rapela, 1975) , hypoxia (Traystman, Fitzgerald and Loscutoff, 1978; Traystman and Fitzgerald, 1981) and ability to autoregulate (Rapela and Green, 1964) using this technique has been previously demonstrated. In the absence of increased venous outflow pressures ( > 2 mm Hg), this method of CBF measurement compares favourably with CBF measured by the injection of microspheres (Wagner and Traystman, 1983) .
Hypoxia and hypercapnia, and blood-gas analysis
Arterial hypoxia was produced through decreasing arterial oxygen content by introducing a gas mixture containing 6.5% oxygen and 93.5% nitrogen to the inspiratory limb of the respirator. Arterial carbon dioxide tension was maintained constant throughout. Hypoxia was maintained for 10-15 min to allow for measurement under near steady-state conditions. The CBF response to hypercapnia was evaluated by introducing likewise a carbon dioxide-containing gas mixture. Five and 10 percent carbon dioxide in air were utilized as the gas mixtures, and hypercapnia was maintained for 10 min at each concentration so that near steady-state measurements could be obtained.
Arterial and cerebral venous blood samples were taken directly from the femoral artery and cerebral venous outflow cannulae, respectively. The design of the study was such that each dog acted as its own control for hypoxia and hypercapnia. Arterial oxygen tension (Pao,), carbon dioxide tension (Pa COt ) and pH were measured at 37 °C immediately after the withdrawal of the samples (Radio- meter BMS3). The electrodes were calibrated with air (20.8% oxygen), and mixtures of oxygen in nitrogen (8%) and 5 and 10% carbon dioxide in air were analysed to a precision of 0.1 %. The pH electrode was calibrated with standard phosphate buffers (6.840; 7.381). Oxygen saturation and haemoglobin were measured also immediately after sampling (Instrumentation Laboratories Co-oximeter Model 282). Electrodes were calibrated before and after each set of samples. Arterial and venous oxygen content were calculated from the measured oxygen saturation and haemoglobin concentration. CMRo 2 was calculated by multiplying CBF by the arterial to cerebro-venous oxygen content difference.
CBF autoregulation limits were also examined. Autoregulation in these studies was defined as the ability of the brain to maintain constant CBF despite wide variations in arterial pressure. The lower limit of cerebral autoregulation was determined by removal of blood from the femoral artery in 100-ml increments. A stabilization period of approximately 2 min was allowed after the removal of each aliquot of blood. As we were able to monitor CBF continuously, we were able to determine readily the stability of the CBF. In every instance, CBF was constant during the times immediately before and after the determination of CBF. The lower limit of autoregulation was determined visually as the mean arterial pressure at which CBF did decrease with a decrease in arterial pressure. In most animals, 600-1000 ml of blood was removed, and the determination of the lower limit of autoregulation usually required 20 min. The upper limit of cerebral autoregulation was determined by increasing mean arterial pressure in 20-mm Hg increments (noradrenaline 4 |ig ml" 1 ) and maintaining that value for approximately 2 min. The upper limit of autoregulation was determined visually as the mean arterial pressure at which CBF increased with an increase in arterial pressure. Generally this procedure was completed within 20 min.
Plan of investigation and data analysis
The direct effect of alfentanil 0.32 mg kg" 1 i.v. on CBF and CMRo, was studied in group 1 animals (n = 6) anaesthetized with pentobarbitone 30 mg kg" 1 i.v. In group 2 animals (n -5) anaesthetized with pentobarbitone 30 mg kg" 1 i.v. and in group 3 animals anaesthetized with alfentanil 0.32 mg kg" 1 i.v. plus pentobarbitone 1-2 mg kg" 1 i.v. and a continuous infusion of alfentanil 0.32 mg kg" 1 h" 1 , the responses to hypoxia, hypercapnia and the upper and lower limits of cerebral autoregulation were determined. Within groups 2 and 3, the order of interventions was randomized and the animals were allowed a stabilization period (about 15 min) between each intervention. In group 1, findings before and after the injection of alfentanil were evaluated using a paired Student's t test. In groups 2 and 3, statistical analysis was performed using analysis of variance (Human Systems Dynamics, Northridge, California) for between-within variables for hypoxia, hypercapnia and limits of autoregulation. P < 0.05 was considered significant. All values in text and figures are shown as mean± SEM.
RESULTS
Haemodynamic, blood-gas and pH changes for all groups of animals are presented in table I. In group 1, alfentanil 0.32 mg kg" 1 i.v. decreased mean arterial pressure (MAP) to 68 % of control 2 min following injection. CBF and CMRo, remained unchanged from their control values, whereas cerebral vascular resistance (CVR) had decreased to 66 % of control 2 min following the injection.
In the animals in group 2, Pa Ot was decreased from 12.6±1.1 to 3.2±0.13kPa, and CBF increased to 285 % of control and CVR decreased to 57% of control. In group 3, as P&Q X was decreased from 12.1 ±0.5 to 2.4±0.13 kPa, CBF increased to 308 % of control and CVR decreased to 53% of control. The CBF response to hypoxia was greater in group 3 compared with group 2 animals; however, the P&o t Bn(^ arterial oxygen content were also lower in group 3. CMRo 2 was unchanged from control in group 2, but was decreased to 70 % of control in group 3, with the more severe hypoxia.
In group 2 as arterial carbon dioxide tension (Pa COt ) was increased from 4.1 ±0.27 to 6.7 ±0.4 and then to 9.2±0.67 kPa, CBF increased to 152 and 252% of control, respectively, and CVR decreased to 66 and 41 % of control, respectively. Both pH and CMRo, were reduced significantly. In group 3, as Pa COl was increased from control (4.7±0.13 to 6.3±0.27) kPa and then to 8.9 ±0.27 kPa, CBF increased to 141 and 209% of control, respectively, and CVR decreased to 77 and 57 % of control, respectively. As in group 2, pH and CMRo, decreased significantly with hypercapnia. Figure 1 shows the response of CBF, CVR, and CMRo, to hypoxia in group 2 animals anaesthetized with pentobarbitone and group 3 animals anaesthetized with alfentanil (plus small amounts of barbiturate). With both basal anaesthetics, the CBF increased to approximately 300 % of control during hypoxia while the CVR decreased to about 60% of control. CMRo, was unchanged in group 2 animals anaesthetized with barbiturate, but was decreased in group 3 animals anaesthetized with alfentanil plus small amounts of barbiturate. Figure 2 shows the response of CBF, CVR and CMROj to hypercapnia in animals anaesthetized with barbiturate (group 2) and alfentanil (group 3). Five and 10 percent carbon dioxide increased CBF by approximately 175 and 250% of control, respectively. CVR decreased to about 75% and 50 % of control in both groups and CMRo, was decreased in both groups by hypercapnia. CMRo 2 was unchanged from control in group 2 animals at the lower Pa COl value.
The upper and lower limits of cerebral autoregulation were determined in group 2 animals anaesthetized with barbiturate and group 3 animals anaesthetized with alfentanil plus small amounts of barbiturate. The lower and upper limits of autoregulation in group 2 were 48 ± 5 and 182±7mmHg, respectively. The limits of autoregulation in group 3 were 46 ±5 and 190 ± 3 mm Hg and these limits were not different from group 2 animals anaesthetized with barbiturate.
DISCUSSION
In this study, the cerebral venous outflow technique (Rapela and Green, 1964) , in which transient changes in CBF could be monitored continuously, was used and the response of CBF and CMRo, to any intervention observed. While one advantage of this technique is that it measures CBF nearly devoid of extracerebral contamination, a disadvantage of this model is the need for anaesthesia during the surgical preparation. Therefore, we have no observation of the effects of alfentanil in the unanaesthetized animal. Baseline CBF in this study was similar to our recent study of fentanyl (McPherson and Traystman, 1984) , but was somewhat higher than those previously reported (Traystman, Fitzgerald and Loscutoff, 1978; Traystman and Fitzgerald, 1981) . As in our previous study (McPherson and Traystman, 1984) , control CBF was around 30 ml min" 1 , whereas in the earlier studies control flows were 20-23 ml min"
1 . Basal CBF in this study was at a lower baseline arterial oxygen content (15 vol%), whereas in previous studies, baseline arterial oxygen content was about 19 vol% and CBF was somewhat lower. In fact, a CBF of 30 ml min" 1 at an arterial oxygen content of 15% vol% is consistent with our previous studies of the effect of decreased arterial oxygen content on CBF (Traystman, Fitzgerald and Loscutoff, 1978; Traystman and Fitzgerald, 1981) .
Alfentanil 0.32 mg kg" 1 i.v., a dose twice that shown to cause profound analgesia and anaesthesia in both animals and man (Nauta et al., 1983) , did not alter CBF despite a substantial decrease in MAP (40 mm Hg). An advantage of the venous outflow technique is the ability to observe transient changes in CBF. Observations were made immediately after the administration of the alfentanil and, although CBF was unchanged, CVR decreased significantly. This was a consequence of the decreased MAP and unchanged CBF and suggests that the decrease in CVR was a normal adjustment to maintain CBF constant in response to a decrease in MAP within the autoregulation range.
We studied the effect of alteration in MAP on CBF using haemorrhagic hypotension and noradrenaline-induced hypertension. Noradrenaline has been shown not to cross the blood-brain barrier and thus has no direct cerebral vascular effect when given i.v. (O'Neill and Traystman, 1977) . The limits of autoregulation were similar to those reported by others (Rapela and Green, 1964) and in our previous study of fentanyl (McPherson and Traystman, 1984) . These data suggest that increases in CBF in the presence of alfentanil and small amounts of barbiturates would be less with hypertension than that noted in the presence of inhalation agents, which have been shown to decrease the ability of cerebral vessels to autoregulate in a dose-dependent manner (Miletich et al., 1976; Morita et al., 1977; Todd and Drummond, 1984) .
The lower limit of autoregulation found in this study was also comparable to those reported previously (Rapela and Green, 1964; McPherson and Traystman, 1984) . CVR was decreased to a similar value in animals anaesthetized with barbiturate and animals anaesthetized with alfentanil plus small amounts of barbiturate, and the CBF was unchanged. This suggests that alfentanil plus small doses of barbiturate does not interfere with maintenance of CBF at relatively low arterial pressures. Thus these data suggest that alfentanil anaesthesia would be an acceptable anaesthetic in situations in which cerebral perfusion pressure is low, such as hypovolaemic hypotension or carotid surgery.
We have demonstrated an essentially linear increase in CBF with increases in Pa COl in animals anaesthetized with alfentanil and small doses of barbiturate which did not differ from the effect in animals anaesthetized with barbiturate only. This differs from situations when anaesthetic doses of anaesthetic gases are administered, in which the CBF response to carbon dioxide is altered (Miletich et al., 1976) . These data suggest that alfentanil anaesthesia would allow manipulation of ICP by inducing alterations in P&c OlHypercapnia resulted in a decrease in CMRo s in both barbiturate-and alfentanil-anaesthetized animals. This decrease in CMRo a occurs in anaesthetized but not sedated animals (Berntmann and Dahlgren, 1979) . The mechanism of maintenance of CMROj in unanaesthetized animals was considered to be an increased catecholamine turnover as a result of hypercapnia and a resultant increase in CMROj. Both anaesthesia and propranolol have been shown to prevent the increase in CMRo 2 caused by hypercapnia (Berntmann and Dalgren, 1979) ; the mechanism of the decrease in CMROj remains unclear.
CBF increased in response to hypoxia both in animals anaesthetized with barbiturate and animals anaesthetized with alfentanil. CBF increased to 3 times control during hypoxia in both groups; however, CMROj was not decreased by hypoxia in animals anaesthetized with barbiturate only. CMRo 2 was decreased during hypoxia in animals anaesthetized with alfentanil. This occurred because the Pa Ol and arterial oxygen content were decreased more in the alfentanil-anaesthetized animals than in barbiturate-anaesthetized animals, and the CBF response in those animals was insufficient to offset the reduction in oxygen delivery. These data suggest that alfentanil plus small doses of barbiturate is not different from moderate doses of barbiturate in its lack of adverse affects on the cerebral hypoxic response.
In summary, our data demonstrate that highdose alfentanil in the presence of small doses of pentobarbitone does not alter cerebral haemodynamic responses to hypoxia or hypercapnia. In addition, the lower and upper limits of autoregulation are not altered by alfentanil. Since the normal cerebral compensatory mechanisms appears to be intact with high doses of alfentanil and since there is a well documented cardiovascular stability with alfentanil, this suggests that high doses of alfentanil would be an acceptable anaesthetic technique in neurosurgical patients.
